121 related articles for article (PubMed ID: 37586075)
1. CXCL10 Recruitment of γδ T Cells into the Hypoxic Bone Marrow Environment Leads to IL17 Expression and Multiple Myeloma Progression.
Wang J; Peng Z; Guo J; Wang Y; Wang S; Jiang H; Wang M; Xie Y; Li X; Hu M; Xie Y; Cheng H; Li T; Jia L; Song J; Wang Y; Hou J; Liu Z
Cancer Immunol Res; 2023 Oct; 11(10):1384-1399. PubMed ID: 37586075
[TBL] [Abstract][Full Text] [Related]
2. Alterations in Intestinal Microbiota Lead to Production of Interleukin 17 by Intrahepatic γδ T-Cell Receptor-Positive Cells and Pathogenesis of Cholestatic Liver Disease.
Tedesco D; Thapa M; Chin CY; Ge Y; Gong M; Li J; Gumber S; Speck P; Elrod EJ; Burd EM; Kitchens WH; Magliocca JF; Adams AB; Weiss DS; Mohamadzadeh M; Grakoui A
Gastroenterology; 2018 Jun; 154(8):2178-2193. PubMed ID: 29454797
[TBL] [Abstract][Full Text] [Related]
3. Multiple Myeloma Impairs Bone Marrow Localization of Effector Natural Killer Cells by Altering the Chemokine Microenvironment.
Ponzetta A; Benigni G; Antonangeli F; Sciumè G; Sanseviero E; Zingoni A; Ricciardi MR; Petrucci MT; Santoni A; Bernardini G
Cancer Res; 2015 Nov; 75(22):4766-77. PubMed ID: 26438594
[TBL] [Abstract][Full Text] [Related]
4. γδ T cells attenuate bleomycin-induced fibrosis through the production of CXCL10.
Pociask DA; Chen K; Choi SM; Oury TD; Steele C; Kolls JK
Am J Pathol; 2011 Mar; 178(3):1167-76. PubMed ID: 21356368
[TBL] [Abstract][Full Text] [Related]
5. Interleukin 17, Produced by γδ T Cells, Contributes to Hepatic Inflammation in a Mouse Model of Biliary Atresia and Is Increased in Livers of Patients.
Klemann C; Schröder A; Dreier A; Möhn N; Dippel S; Winterberg T; Wilde A; Yu Y; Thorenz A; Gueler F; Jörns A; Tolosa E; Leonhardt J; Haas JD; Prinz I; Vieten G; Petersen C; Kuebler JF
Gastroenterology; 2016 Jan; 150(1):229-241.e5. PubMed ID: 26404950
[TBL] [Abstract][Full Text] [Related]
6. Homing characteristics of donor T cells after experimental allogeneic bone marrow transplantation and posttransplantation therapy for multiple myeloma.
van der Voort R; Volman TJ; Verweij V; Linssen PC; Maas F; Hebeda KM; Dolstra H
Biol Blood Marrow Transplant; 2013 Mar; 19(3):378-86. PubMed ID: 23266741
[TBL] [Abstract][Full Text] [Related]
7. Anti-tumor cytotoxicity of gammadelta T cells expanded from peripheral blood cells of patients with myeloma and lymphoma.
Saitoh A; Narita M; Watanabe N; Tochiki N; Satoh N; Takizawa J; Furukawa T; Toba K; Aizawa Y; Shinada S; Takahashi M
Med Oncol; 2008; 25(2):137-47. PubMed ID: 18488155
[TBL] [Abstract][Full Text] [Related]
8. Myeloma cells exhibit an increase in proteasome activity and an enhanced response to proteasome inhibition in the bone marrow microenvironment in vivo.
Edwards CM; Lwin ST; Fowler JA; Oyajobi BO; Zhuang J; Bates AL; Mundy GR
Am J Hematol; 2009 May; 84(5):268-72. PubMed ID: 19296472
[TBL] [Abstract][Full Text] [Related]
9. Radiation-Induced Dermatitis is Mediated by IL17-Expressing γδ T Cells.
Liao W; Hei TK; Cheng SK
Radiat Res; 2017 Apr; 187(4):454-464. PubMed ID: 28406748
[TBL] [Abstract][Full Text] [Related]
10. Erythroblast apoptosis and microenvironmental iron restriction trigger anemia in the VK*MYC model of multiple myeloma.
Bordini J; Bertilaccio MT; Ponzoni M; Fermo I; Chesi M; Bergsagel PL; Camaschella C; Campanella A
Haematologica; 2015 Jun; 100(6):834-841. PubMed ID: 25715406
[TBL] [Abstract][Full Text] [Related]
11. Subclone-specific microenvironmental impact and drug response in refractory multiple myeloma revealed by single-cell transcriptomics.
Tirier SM; Mallm JP; Steiger S; Poos AM; Awwad MHS; Giesen N; Casiraghi N; Susak H; Bauer K; Baumann A; John L; Seckinger A; Hose D; Müller-Tidow C; Goldschmidt H; Stegle O; Hundemer M; Weinhold N; Raab MS; Rippe K
Nat Commun; 2021 Nov; 12(1):6960. PubMed ID: 34845188
[TBL] [Abstract][Full Text] [Related]
12. Runx2 Deficiency in Osteoblasts Promotes Myeloma Resistance to Bortezomib by Increasing TSP-1-Dependent TGFβ1 Activation and Suppressing Immunity in Bone Marrow.
Zhang C; Xu X; Trotter TN; Gowda PS; Lu Y; Suto MJ; Javed A; Murphy-Ullrich JE; Li J; Yang Y
Mol Cancer Ther; 2022 Feb; 21(2):347-358. PubMed ID: 34907087
[TBL] [Abstract][Full Text] [Related]
13. Myeloma plasma cells alter the bone marrow microenvironment by stimulating the proliferation of mesenchymal stromal cells.
Noll JE; Williams SA; Tong CM; Wang H; Quach JM; Purton LE; Pilkington K; To LB; Evdokiou A; Gronthos S; Zannettino AC
Haematologica; 2014 Jan; 99(1):163-71. PubMed ID: 23935020
[TBL] [Abstract][Full Text] [Related]
14. Hypoxia induces chemoresistance to proteasome inhibitors through orchestrating deSUMOylation and ubiquitination of SRC-3 in multiple myeloma.
Guo J; Lv Y; Wang S; Peng Z; Xie Y; Wang Y; Jiang H; Li X; Wang M; Hu M; Mu J; Wang J; Xie Y; Cheng X; Zhao Z; Liu Z
Oncogene; 2022 Nov; 41(45):4971-4979. PubMed ID: 36209257
[TBL] [Abstract][Full Text] [Related]
15. Low-dose bortezomib increases the expression of NKG2D and DNAM-1 ligands and enhances induced NK and γδ T cell-mediated lysis in multiple myeloma.
Niu C; Jin H; Li M; Zhu S; Zhou L; Jin F; Zhou Y; Xu D; Xu J; Zhao L; Hao S; Li W; Cui J
Oncotarget; 2017 Jan; 8(4):5954-5964. PubMed ID: 27992381
[TBL] [Abstract][Full Text] [Related]
16. The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects.
Hurchla MA; Garcia-Gomez A; Hornick MC; Ocio EM; Li A; Blanco JF; Collins L; Kirk CJ; Piwnica-Worms D; Vij R; Tomasson MH; Pandiella A; San Miguel JF; Garayoa M; Weilbaecher KN
Leukemia; 2013 Feb; 27(2):430-40. PubMed ID: 22763387
[TBL] [Abstract][Full Text] [Related]
17. Repurposing tofacitinib as an anti-myeloma therapeutic to reverse growth-promoting effects of the bone marrow microenvironment.
Lam C; Ferguson ID; Mariano MC; Lin YT; Murnane M; Liu H; Smith GA; Wong SW; Taunton J; Liu JO; Mitsiades CS; Hann BC; Aftab BT; Wiita AP
Haematologica; 2018 Jul; 103(7):1218-1228. PubMed ID: 29622655
[TBL] [Abstract][Full Text] [Related]
18. Immune checkpoint inhibition improves antimyeloma activity of bortezomib and STING agonist combination in Vk*MYC preclinical model.
Sokolowska O; Rodziewicz-Lurzynska A; Pilch Z; Kedzierska H; Chlebowska-Tuz J; Sosnowska A; Szumera-Cieckiewicz A; Sokol K; Barankiewicz J; Salomon-Perzynski A; Ciepiela O; Lech-Maranda E; Golab J; Nowis D
Clin Exp Med; 2023 Sep; 23(5):1563-1572. PubMed ID: 36044158
[TBL] [Abstract][Full Text] [Related]
19. The bone marrow microenvironment enhances multiple myeloma progression by exosome-mediated activation of myeloid-derived suppressor cells.
Wang J; De Veirman K; De Beule N; Maes K; De Bruyne E; Van Valckenborgh E; Vanderkerken K; Menu E
Oncotarget; 2015 Dec; 6(41):43992-4004. PubMed ID: 26556857
[TBL] [Abstract][Full Text] [Related]
20. Pivotal role of dermal IL-17-producing γδ T cells in skin inflammation.
Cai Y; Shen X; Ding C; Qi C; Li K; Li X; Jala VR; Zhang HG; Wang T; Zheng J; Yan J
Immunity; 2011 Oct; 35(4):596-610. PubMed ID: 21982596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
